A Phase 2 study enrolling patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. This study assesses the efficacy and safety of CTX-009. The primary outcome is ORR (Overall Response Rate).
A Phase 2 study enrolling patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. This study assesses the efficacy and safety of CTX-009. The primary outcome is ORR (Overall Response Rate).